Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

Non-small Cell Lung CancerBreast CancerProstate Cancer

Interventions

DRUG

imexon

IV variable dosages, days 1-5 every 21 days for duration of study

DRUG

docetaxel

IV once every 21 days for duration of study

Trial Locations (1)

Investigational Site 008, Houston